Fortress Biotech(FBIO) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous squamous cell carcinoma Miami, FL – November 14, 2024 – Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets ...